Source: Eur Respir J 2016; 47:E66
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
ERJ June Podcast: unfavourable effects of oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47:E66

Member's Comments

No comment yet.

Related content which might interest you: ERJ March Podcast: Novel therapies in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 19E5303; 10.1183/13993003.E5303-2019 Year: 2019 Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis Source: Eur Respir J 2016; 47:1776-1784 Year: 2016 Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns Source: Eur Respir J 2016; 48: 1524-1526 Year: 2016 Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns Source: Eur Respir J 2016; 48: 1523-1524 Year: 2016 ERJ August Podcast: management of chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2016; 48: E68 Year: 2016 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 ERJ January Podcast: clinical guidelines for chronic pulmonary aspergillosis Source: Eur Respir J 2016; 47: E61 Year: 2016 Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? Source: Eur Respir Rev 2011; 20: 201-207 Year: 2011 Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study Source: Eur Respir J 2012; 40: 101-109 Year: 2012 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial “impact” beyond any expectation Source: Eur Respir J, 57 (3) 2003111; 10.1183/13993003.03111-2020 Year: 2021 Triple therapy in idiopathic pulmonary fibrosis: an alarming press release Source: Eur Respir J 2012; 39: 805-806 Year: 2012 Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021 Year: 2021 Japanese guideline for the treatment of idiopathic pulmonary fibrosis 2017 Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 246s Year: 2007 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016